CETN2

Across TCGA pan-cancer cohorts, CETN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CETN2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CETN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CETN2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where CETN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.955	1.000	.013	26	view →
CCRCC	DFS	Median	II,III,IV	0.887	0.283	.012	12	view →
LSCC	DFS	Median	II,III,IV	0.867	0.973	.009	9	view →
UCEC	OS	Tertile	II,III,IV	0.547	1.000	.018	8	view →
LUAD	DFS	Median	All	0.891	1.000	.014	5	view →
PDAC	OS	Median	All	0.888	0.761	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CETN2–HNSC (OS)

Open the HNSC breakdown →